Initiation of Buprenorphine During Incarceration and Retention in Treatment Upon Release

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2013 Apr 2

PMID 23541303

Citations 35

Authors

Nickolas Zaller

Michelle McKenzie

Peter D Friedmann

Traci C Green

Samuel McGowan

Josiah D Rich

Affiliations

Soon will be listed here.

Abstract

We report here on a feasibility study of initiating buprenorphine/naloxone prior to release from incarceration and linking participants to community treatment providers upon release. The study consisted of a small number of Rhode Island (RI) prisoners (N = 44) diagnosed with opioid dependence. The study design is a single arm, open-label pilot study with a 6-month follow up interview conducted in the community. However, a natural experiment arose during the study comparing pre-release initiation of buprenorphone/naloxone to initiation post-release. Time to post-release prescriber appointment (mean days) for initiation of treatment outside Rhode Island Department of Corrections (RIDOC) versus inside RIDOC was 8.8 and 3.9, respectively (p = .1). Median post release treatment duration (weeks) for outside RIDOC versus inside RIDOC was 9 and 24, respectively (p = .007). We conclude that initiating buprenorphine/naloxone prior to release from incarceration may increase engagement and retention in community-based treatment.

Citing Articles

Medication for opioid use disorder service delivery in carceral facilities: update and summary report.

Berk J, South A, Martin M, James M, Miller C, Haber L Health Justice. 2025; 13(1):8.

PMID: 39891797 PMC: 11786385. DOI: 10.1186/s40352-025-00317-9.

The association between attitudes and the provision of medications for opioid use disorder (MOUD) in United States jails.

Pfaff A, Cochran A, Vechinski J, Molfenter T, Zayas-Caban G Drug Alcohol Depend Rep. 2024; 10:100211.

PMID: 38205144 PMC: 10776447. DOI: 10.1016/j.dadr.2023.100211.

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV.

Parchinski K, Di Paola A, Wilson A, Springer S Drug Alcohol Depend Rep. 2023; 7:100159.

PMID: 37159815 PMC: 10163604. DOI: 10.1016/j.dadr.2023.100159.

Incarceration status at buprenorphine initiation and OUD treatment outcomes during pregnancy.

Nguyen A, Shadowen H, Shadowen C, Thakkar B, Knittel A, Martin C Front Psychiatry. 2023; 14:1157611.

PMID: 37124262 PMC: 10133465. DOI: 10.3389/fpsyt.2023.1157611.

Development and use of a checklist for the implementation of medication for opioid use disorder in jails.

Ludwig A, Monico L, Blue T, Gordon M, Schwartz R, Mitchell S Implement Res Pract. 2023; 3:26334895221101214.

PMID: 37091098 PMC: 9924266. DOI: 10.1177/26334895221101214.

References

Fhima A, Henrion R, Lowenstein W, Charpak Y . [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)]. Ann Med Interne (Paris). 2001; 152 Suppl 3:IS26-36. View

Johnson R, Strain E, Amass L . Buprenorphine: how to use it right. Drug Alcohol Depend. 2003; 70(2 Suppl):S59-77. DOI: 10.1016/s0376-8716(03)00060-7. View

Johanson C, Arfken C, di Menza S, Schuster C . Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2011; 120(1-3):190-5. DOI: 10.1016/j.drugalcdep.2011.07.019. View

Taxman F, Perdoni M, Harrison L . Drug treatment services for adult offenders: the state of the state. J Subst Abuse Treat. 2007; 32(3):239-54. PMC: 2266078. DOI: 10.1016/j.jsat.2006.12.019. View

Zaller N, Bazazi A, Velazquez L, Rich J . Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities. Int J Environ Res Public Health. 2009; 6(2):787-97. PMC: 2672350. DOI: 10.3390/ijerph6020787. View

Harris D, Jones R, Welm S, Upton R, Lin E, Mendelson J . Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000; 61(1):85-94. DOI: 10.1016/s0376-8716(00)00126-5. View

Rich J, McKenzie M, Dickman S, Bratberg J, Lee J, Schwartz R . An Adverse Reaction to Buprenorphine/Naloxone Induction in Prison: A Case Report. Addict Disord Their Treat. 2011; 10(4):199-200. PMC: 3222590. DOI: 10.1097/ADT.0b013e3182133949. View

Lee J, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S . Buprenorphine-naloxone maintenance following release from jail. Subst Abus. 2012; 33(1):40-7. PMC: 3310898. DOI: 10.1080/08897077.2011.620475. View

McLellan A, Kushner H, Metzger D, Peters R, Smith I, Grissom G . The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9(3):199-213. DOI: 10.1016/0740-5472(92)90062-s. View

10.

Alford D, Labelle C, Kretsch N, Bergeron A, Winter M, Botticelli M . Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011; 171(5):425-31. PMC: 3059544. DOI: 10.1001/archinternmed.2010.541. View

11.

Hammett T . HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. Am J Public Health. 2006; 96(6):974-8. PMC: 1470637. DOI: 10.2105/AJPH.2005.066993. View

12.

Rich J, Boutwell A, Shield D, Key R, McKenzie M, Clarke J . Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005; 82(3):411-9. PMC: 3456063. DOI: 10.1093/jurban/jti072. View

13.

Gordon M, Kinlock T, Miller P . Medication-assisted treatment research with criminal justice populations: challenges of implementation. Behav Sci Law. 2011; 29(6):829-45. PMC: 3243915. DOI: 10.1002/bsl.1015. View

14.

Dasgupta N, Bailey E, Cicero T, Inciardi J, Parrino M, Rosenblum A . Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010; 11(7):1078-91. DOI: 10.1111/j.1526-4637.2010.00877.x. View

15.

Alho H, Sinclair D, Vuori E, Holopainen A . Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2006; 88(1):75-8. DOI: 10.1016/j.drugalcdep.2006.09.012. View

16.

Cropsey K, Lane P, Hale G, Jackson D, Clark C, S Ingersoll K . Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drug Alcohol Depend. 2011; 119(3):172-8. PMC: 3214606. DOI: 10.1016/j.drugalcdep.2011.06.021. View

17.

Kinlock T, Gordon M, Schwartz R, Fitzgerald T . Developing and Implementing a New Prison-Based Buprenorphine Treatment Program. J Offender Rehabil. 2010; 49(2):91-109. PMC: 2868193. DOI: 10.1080/10509670903534951. View

18.

Yokell M, Zaller N, Green T, Rich J . Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011; 4(1):28-41. PMC: 3154701. DOI: 10.2174/1874473711104010028. View

19.

Albizu Garcia C, Correa G, Viver A, Kinlock T, Gordon M, Avila C . Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico. J Addict Med. 2011; 1(3):126-32. DOI: 10.1097/ADM.0b013e31814b8880. View

20.

Fiellin D, Rosenheck R, Kosten T . Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry. 2001; 158(8):1200-4. DOI: 10.1176/appi.ajp.158.8.1200. View